Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV

The modest protective effects of the RV144 HIV-1 vaccine trial have prompted the further exploration of improved poxvirus vector systems that can yield better immune responses and protection. In this study, a recombinant lumpy skin disease virus (LSDV) expressing HIV-1 CAP256.SU gp150 (Env) and a su...

Full description

Bibliographic Details
Main Authors: Ros Chapman, Michiel van Diepen, Nicola Douglass, Shireen Galant, Mohamed Jaffer, Emmanuel Margolin, Phindile Ximba, Tandile Hermanus, Penny L. Moore, Anna-Lise Williamson
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Vaccines
Subjects:
LSDV
lumpy skin disease
vaccine
HIV-1
vector
poxvirus
Online Access:https://www.mdpi.com/2076-393X/9/11/1281

Internet

https://www.mdpi.com/2076-393X/9/11/1281

Similar Items